A LIFE-CHANGING cystic fibrosis medicine which significantly extends the lives of patients while saving families up to a quarter of a million dollars a year will be subsidised.
From October 1, Orkambi will be available on the Pharmaceutical Benefits Scheme for all patients over the age of 6 years old and who have the most the most common form of cystic fibrosis – two copies of the f508del mutation in the CFTR gene.
Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.
Member for Forrest Nola Marino said the medicine would provide over 1,200 Australian patients, and their families, with a longer and better life.
Source: Collie Mail.